InsiderTrades

Form 4 for AVTX Avalo Therapeutics, Inc.

Accepted 2026-06-25 17:24:52 ET · period of report 2026-06-23 · accession 0001918845-26-000020 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DT 2026-06-25 17:24 2026-06-23 AVTX Doyle Mittie Chief Medical Off M - OptEx $8.04 +1,450 53.2K +3% +$11.7K
DT 2026-06-25 17:24 2026-06-23 AVTX Doyle Mittie Chief Medical Off S - Sale+OE $18.00 -1,450 51.8K -3% -$26.1K
DT 2026-06-25 17:24 2026-06-23 AVTX Doyle Mittie Chief Medical Off M - OptEx $0.00 -1,450 116.9K -1% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-06-23 M A 1,450 $8.04 53,226 D — — (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
2 Common Common Stock 2026-06-23 S D 1,450 $18.00 51,776 D — — (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
3 Derivative Stock Option (Right to Buy) 2026-06-23 M D 1,450 $0.00 116,871 D $8.04 · — to 2035-01-28 1,450 Common Stock (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. (F2) The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.